<DOC>
	<DOCNO>NCT02246686</DOCNO>
	<brief_summary>The study investigate efficacy STW5-II add-on therapy rate remission patient mild moderate ulcerative colitis acute flare .</brief_summary>
	<brief_title>Efficacy/Safety Pilot Study Investigate Iberogast N 's Efficacy Mild Moderate Colitis Ulcerosa Patients</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<criteria>Patients mild moderate active ulcerative colitis ( UC ) , i.e . Clinical Activity Index ( CAI ) â‰¥ 5 10 point ( include ) Patients active UC treat independent participation current study oral mesalazine least 14 day maximal 28 day Visit 2 Age 18 80 year ( include ) UC may reach leftsided colitis pancolitis Severe form UC ( CAI &gt; 10 ) Crohn 's disease , infectious colitis undetermined colitis Steroid dependence steroid resistance Concomitant medication oral steroid , oral topic budesonide , biologicals , immune modifier , immunosuppressant Antibiotics screen visit , course study shortterm use noncolitic affliction allow , document Prior medication biologicals , immune modifier immunosuppressant &lt; 3 month washout Total colectomy Known allergies component STW5II Severe allergic diathesis Topical mesalazine application Known intolerance azo dye E110 E151</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Iberogast N</keyword>
	<keyword>Mild moderate ulcerative colitis</keyword>
	<keyword>add-on therapy</keyword>
	<keyword>efficacy</keyword>
</DOC>